XOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

XOMA Royalty Corporation (NASDAQ:XOMA)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $32.25 and traded as high as $42.16. XOMA Royalty shares last traded at $42.00, with a volume of 105,495 shares trading hands.

Analysts Set New Price Targets

A number of analysts have weighed in on XOMA shares. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research note on Thursday, April 30th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Weiss Ratings raised XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Finally, Leerink Partners restated an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $53.75.

XOMA Royalty Stock Performance

The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96. The firm’s fifty day moving average price is $41.12 and its 200-day moving average price is $32.25. The firm has a market cap of $526.68 million, a price-to-earnings ratio of 26.75 and a beta of 0.88.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The company had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. Analysts expect that XOMA Royalty Corporation will post 0.9 earnings per share for the current year.

Institutional Trading of XOMA Royalty

Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in shares of XOMA Royalty during the fourth quarter worth about $27,000. Russell Investments Group Ltd. boosted its position in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 756 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the period. JPMorgan Chase & Co. grew its stake in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in XOMA Royalty during the 2nd quarter worth approximately $116,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.